Abstract: The disclosure relates to a glycoconjugate vaccine conferring protection against Francisella tularensis infections and a method to manufacture a glycoconjugate antigen.

Abstract: The disclosure relates to an oligosaccharyltransferase polypeptides and their use in the synthesis of glycoconjugates in bacterial cells; vaccines and immunogenic compositions comprising said glycoconjugates and their use in the prevention and/or treatment of bacterial infection. Bacterial expression system comprising said oligosaccharyltransferase polypeptides are also disclosed.

Abstract: The invention relates to microbial host cells engineered to produce glycoconjugate vaccines by stable integration of an acceptor protein and an oligosaccharyltransferase into the host's genome, wherein expression of the oligosaccharyltransferase is regulated.

Abstract: The disclosure relates to attenuated bacterial cells expressing glycans and glycoconjugate antigens and their use in the manufacture of whole cell vaccines effective at preventing or treating bacterial infections in non-human species.

Abstract: A mosquito attractant composition is described comprising heptanal, octanal, nonanal, (E)-2-octenal and (E)-2-decenal. More particularly a composition wherein the compounds are present in the following proportions: nonanal 1.00, octanal 0.32±0.16, heptanal 0.06±0.03, (E)-2-octenal 0.04±0.02 and (E)-2-decenal 0.13±0.065.

Abstract: The disclosure relates to a glycoconjugate vaccine conferring protection against Francisella tularensis infections and a method to manufacture a glycoconjugate antigen.

Abstract: A novel cytokine, U83A, is described, as are variant forms of the cytokine, having a wide range of agonistic and antagonistic activity against chemokine receptors. Uses of the chemokine in treatment of a range of diseases, including cancers and HIV/AIDS, are described.

Abstract: The invention relates to microbial host cells engineered to produce glycoconjugate vaccines by stable integration of an acceptor protein and an oligosaccharyltransferase into the host's genome, wherein expression of the oligosaccharyltransferase is regulated.

Abstract: The invention relates to an isolated African horse sickness virus (AHSV) ssRNA comprising a plurality of mutations; a complementary cell for replication of a vaccinal viral strain from said ssRNA; a vaccinal viral strain derived from said ssRNA; use of said vaccinal viral strain and/or isolated ssRNA in the vaccination of an animal against an infection by AHSV; a method of vaccination comprising same; and a pharmaceutical composition comprising said vaccinal viral strain and/or said isolated ssRNA.

Abstract: The present invention provides compounds for attracting bed bugs, compositions thereof, devices comprising said compositions and their use in the detection, monitoring and control of bed bugs.

Abstract: The invention relates to microbial host cells engineered to produce glycoconjugate vaccines by stable integration of an acceptor protein and an oligosaccharyltransferase into the host's genome, wherein expression of the oligosaccharyltransferase is regulated.

Abstract: The disclosure relates to a glycoconjugate vaccine conferring protection against Francisella tularensis infections and a method to manufacture a glycoconjugate antigen.

Abstract: The disclosure relates to an oligosaccharyltransferase polypeptides and their use in the synthesis of glycoconjugates in bacterial cells; vaccines and immunogenic compositions comprising said glycoconjugates and their use in the prevention and/or treatment of bacterial infection. Bacterial expression system comprising said oligosaccharyltransferase polypeptides are also disclosed.

Abstract: The disclosure relates to attenuated bacterial cells expressing glycans and glycoconjugate antigens and their use in the manufacture of whole cell vaccines effective at preventing or treating bacterial infections in non-human species.

Abstract: The present invention provides compounds for attracting bed bugs, compositions thereof, devices comprising said compositions and their use in the detection, monitoring and control of bed bugs.

Abstract: The invention relates to an isolated African horse sickness virus (AHSV) ssRNA comprising a plurality of mutations; a complementary cell for replication of a vaccinal viral strain from said ssRNA; a vaccinal viral strain derived from said ssRNA; use of said vaccinal viral strain and/or isolated ssRNA in the vaccination of an animal against an infection by AHSV; a method of vaccination comprising same; and a pharmaceutical composition comprising said vaccinal viral strain and/or said isolated ssRNA.

Abstract: The invention relates to deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a pharmaceutical or veterinary composition or formulation comprising at least deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a combination therapeutic comprising at least deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a method of treating a mammal suspected of being infected with, or infected with, C. difficile comprising the use of at least deoxyribonuclease; a method of cleaning or sterilizing a material or product comprising the use of at least deoxyribonuclease; and a cleaning or sterilizing product impregnated with or containing at least deoxyribonuclease.

Abstract: The disclosure relates to a glycoconjugate vaccine conferring protection against Francisella tularensis infections and a method to manufacture a glycoconjugate antigen.

Abstract: The invention relates to microbial host cells engineered to produce glycoconjugate vaccines by stable integration of an acceptor protein and an oligosaccharyltransferase into the host's genome, wherein expression of the oligosaccharyltransferase is regulated.

Abstract: The invention relates to microbial host cells engineered to produce glycoconjugate vaccines by stable integration of an acceptor protein and an oligosaccharyltransferase into the host's genome, wherein expression of the oligosaccharyltransferase is regulated.